Results from the SURMOUNT-5 trial released today show that Eli Lilly's Zepbound (tirzepatide) is superior to Novo Nordisk’s Wegovy (semaglutide). Zepbound achieved a 47% greater relative weight loss than Wegovy. Patients treated with Zepbound lost an average of 20.2% of their body weight (50.3 pounds) over 72 weeks, compared to 13.7% (33.1 pounds) for those on Wegovy.

The study also demonstrated Zepbound's effectiveness in achieving significant weight reduction, with 31.6% of participants losing at least 25% of their body weight, nearly double the 16.1% seen in the Wegovy group. The trial conducted in the U.S. and Puerto Rico included 751 participants without diabetes but with obesity or overweight and at least one weight-related medical condition.

The results could redefine treatment strategies in the obesity market. Unlike semaglutide, which activates GLP-1 receptors, tirzepatide activates both GLP-1 and GIP receptors, offering a broader mechanism of action. Leonard Glass, M.D., Lilly’s senior vice president of global medical affairs, called the findings a step forward for healthcare providers and patients seeking effective solutions for obesity management.

While the results boost Zepbound's competitive advantage, analysts remain measured, noting that they reinforce existing expectations rather than offering new insights. However, the study may help Lilly gain more ground in an increasingly competitive market.

For more information, visit Fierce Pharma.